Chapter 12. Discovery of AZD1152: A Selective Inhibitor of Aurora-B Kinase with Potent Antitumor Activity

  1. Rongshi Li and
  2. Jeffrey A. Stafford
  1. Kevin M. Foote1 and
  2. Andrew A. Mortlock2

Published Online: 28 SEP 2009

DOI: 10.1002/9780470524961.ch12

Kinase Inhibitor Drugs

Kinase Inhibitor Drugs

How to Cite

Foote, K. M. and Mortlock, A. A. (2009) Discovery of AZD1152: A Selective Inhibitor of Aurora-B Kinase with Potent Antitumor Activity, in Kinase Inhibitor Drugs (eds R. Li and J. A. Stafford), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470524961.ch12

Editor Information

  1. Takeda San Diego, Inc., San Diego, CA 92121, USA

Author Information

  1. 1

    Chemistry, AstraZeneca Pharmaceuticals, Macclesfield, Cheshire SK10 4TG, United Kingdom

  2. 2

    Oncology, AstraZeneca Pharmaceuticals, Macclesfield, Cheshire SK10 4TG, United Kingdom

Publication History

  1. Published Online: 28 SEP 2009
  2. Published Print: 2 OCT 2009

Book Series:

  1. Wiley Series in Drug Discovery and Development

Book Series Editors:

  1. Binghe Wang

ISBN Information

Print ISBN: 9780470278291

Online ISBN: 9780470524961

SEARCH

Keywords:

  • AZD 1152 discovery - selective inhibitor of Aurora-B kinase with potent antitumor activity;
  • quinazolines substituted with aminothiazoles;
  • screening cascade updated

Summary

This chapter contains sections titled:

  • Introduction

  • Anilinoquinazolines and Corresponding Pyrimidine and Pyridine Analogs

  • Crystallographic Studies

  • Quinazolines Substituted with Aminothiazoles or Aminothiophenes

  • The Screening Cascade Updated

  • Quinazolines Substituted with Aminopyrazoles

  • AZD1152

  • Summary

  • Acknowledgment

  • References